Navigation Links
A small cut with a big impact

Diseases and injuries trigger warning signals in our cells. As a result, genes are expressed and proteins produced, modified or degraded to adapt to the external danger and to protect the organism. In order to be able to produce a particular protein, the corresponding DNA segment, the gene, needs to be expressed and translated. The DNA is localized in the cell nucleus, and exists as a long string that is coiled and bound by proteins. ARTD1 is one such protein, and therefore has the potential to regulate the expression level of genes through its interaction with DNA.

If cells detect warning signals or foreign bodies like bacteria and viruses in their surroundings, the expression profile of genes changes and an inflammatory response is triggered. To induce changes in gene expression, ARTD1 is removed from particular sites of the DNA. The process by which this is brought about has, until now, remained elusive. The team headed by Professor Michael O. Hottiger from the Institute of Veterinary Biochemistry and Molecular Biology at the University of Zurich has now discovered how ARTD1's DNA recruitment is regulated during inflammation, thereby influencing gene expression and subsequently inflammation.

Molecular scissors

As the researchers demonstrate in Molecular Cell, ARTD1 is cut into two pieces by molecular scissors, the protein caspase 7. Upon cleavage, these pieces can no longer bind to the DNA, thus allowing for more efficient gene expression.

The cleavage of proteins by caspase 7 was so far mainly associated with cell death. "The cleavage of ARTD1 by caspase 7 during inflammation constitutes a new biological function. It permits a new understanding of inflammatory responses and, in the longer term, may lead to the development of new anti-inflammatory drugs," explains Professor Hottiger. The results are of considerable importance because inflammation underlies most diseases, including cancer, immune disorders or metabolic syndrome.


Contact: Michael Hottiger
University of Zurich

Related biology news :

1. Laparoscopy reduces the risk of small-bowel obstruction
2. New analysis helps guide use of erlotinib in advanced non-small cell lung cancer
3. Turning off small RNA
4. Smallest tools could give biggest results in bone repair
5. New species of tiny frog is worlds smallest vertebrate
6. Members of small monkey groups more likely to fight
7. A small step for lungfish, a big step for the evolution of walking
8. Worlds smallest frogs discovered in New Guinea
9. Big pest, small genome
10. Scripps research scientists develop brand new class of small molecules through innovative chemistry
11. CO2 bonds in sea ice: Small living creatures with major impact
Post Your Comments:
(Date:11/19/2015)... -- Although some 350 companies are actively involved in molecular ... according to Kalorama Information. These include Roche Diagnostics, Hologic, Abbott ... of the 6.1 billion-dollar molecular testing market, according to ... Diagnostic s .    ... one company and only a handful of companies can ...
(Date:11/17/2015)... , November 17, 2015 ... 19 novembre  2015.  --> Paris , ... --> DERMALOG, le leader de l,innovation biométrique, a ... fois passeports et empreintes sur la même surface de ... passeports et l,autre pour les empreintes digitales. Désormais, un ...
(Date:11/12/2015)... Nov. 12, 2015  A golden retriever that stayed ... dystrophy (DMD) has provided a new lead for treating ... the Broad Institute of MIT and Harvard and the ... . Cell, pinpoints a protective ... the disease,s effects. The Boston Children,s lab of ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... , Nov. 24, 2015  Twist Bioscience, ... that Emily Leproust, Ph.D., Twist Bioscience chief executive ... Healthcare Conference on December 1, 2015 at 3:10 ... in New York City. --> ... . Twist Bioscience is on Twitter. Sign ...
(Date:11/24/2015)... BC (PRWEB) , ... November 24, 2015 , ... ... our customer, OrthoAccel® Technologies, Inc., on being named to Deloitte's 2015 Technology Fast ... Technologies’ Texas facility, OrthoAccel manufactures AcceleDent®, a FDA-cleared, Class II medical device that ...
(Date:11/24/2015)... HemoShear Therapeutics, LLC, a privately held ... disorders, announced today the appointment of H. ... (BOD). Mr. Watkins is the former president and ... and also served as the chairman of the ... Chairman and CEO of HemoShear Therapeutics. "The combination ...
(Date:11/24/2015)... ... ... Laboratories is pleased to announce that it has completed construction on a new ... 61, USP 62 and USP 51 testing specific to raw materials and will enable ... by one supplier. Management has formally announced that the facility will be ...
Breaking Biology Technology: